Russell Investments Group Ltd. Trims Stock Position in Arvinas, Inc. (NASDAQ:ARVN)

Russell Investments Group Ltd. lessened its position in shares of Arvinas, Inc. (NASDAQ:ARVN) by 28.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 7,627 shares of the company’s stock after selling 3,064 shares during the quarter. Russell Investments Group Ltd.’s holdings in Arvinas were worth $146,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of ARVN. Rhumbline Advisers raised its stake in Arvinas by 0.9% in the 4th quarter. Rhumbline Advisers now owns 87,877 shares of the company’s stock valued at $1,685,000 after purchasing an additional 754 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of Arvinas by 0.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 140,518 shares of the company’s stock worth $2,694,000 after acquiring an additional 777 shares during the period. KBC Group NV raised its position in Arvinas by 77.0% in the 4th quarter. KBC Group NV now owns 2,885 shares of the company’s stock valued at $55,000 after purchasing an additional 1,255 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Arvinas by 10.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,570 shares of the company’s stock worth $279,000 after acquiring an additional 1,367 shares during the last quarter. Finally, LPL Financial LLC lifted its position in shares of Arvinas by 12.5% during the 4th quarter. LPL Financial LLC now owns 18,669 shares of the company’s stock worth $358,000 after purchasing an additional 2,077 shares during the last quarter. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Wall Street Analyst Weigh In

ARVN has been the topic of several recent analyst reports. The Goldman Sachs Group dropped their price target on shares of Arvinas from $15.00 to $12.00 and set a “neutral” rating on the stock in a research note on Thursday, April 17th. Barclays lowered their target price on Arvinas from $48.00 to $32.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd. Bank of America dropped their price target on shares of Arvinas from $54.00 to $28.00 and set a “buy” rating on the stock in a research note on Wednesday, March 12th. HC Wainwright restated a “buy” rating and set a $81.00 target price on shares of Arvinas in a research report on Monday, April 7th. Finally, Oppenheimer downgraded Arvinas from an “outperform” rating to a “market perform” rating in a research note on Tuesday, March 11th. Five analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, Arvinas has an average rating of “Moderate Buy” and an average price target of $34.33.

Arvinas Stock Down 1.0 %

Shares of NASDAQ ARVN opened at $9.05 on Friday. The stock has a market capitalization of $622.39 million, a PE ratio of -3.27 and a beta of 2.30. The firm has a fifty day moving average of $10.58 and a 200-day moving average of $18.09. Arvinas, Inc. has a 52-week low of $5.94 and a 52-week high of $37.38.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same period in the previous year, the business earned ($2.53) EPS. Equities research analysts expect that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.

Insider Buying and Selling

In other Arvinas news, CEO John G. Houston sold 31,338 shares of the business’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $16.72, for a total value of $523,971.36. Following the sale, the chief executive officer now owns 1,157,480 shares of the company’s stock, valued at $19,353,065.60. The trade was a 2.64 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Noah Berkowitz sold 8,658 shares of the business’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.59, for a total transaction of $74,372.22. Following the completion of the transaction, the insider now owns 110,023 shares in the company, valued at approximately $945,097.57. This trade represents a 7.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 50,230 shares of company stock worth $769,402 in the last ninety days. 5.23% of the stock is currently owned by corporate insiders.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.